Journal: Frontiers in Immunology

Article Title: In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment

doi: 10.3389/fimmu.2025.1644437

Figure Lengend Snippet: Screening and analysis of high-affinity epitopes on SOST. (A) ELISA experiments were conducted to identify SOST fragments with strong binding affinity for ROMO, revealing that SOST 114–143 and SOST 143–173 exhibit significantly higher affinity ( P <0.01). (B) A schematic diagram delineating the binding functional regions associated with the high-affinity fragments of SOST. (C) ELISA results indicate that SOST 131–163 displays the highest affinity for ROMO ( P <0.01), thereby identifying it as a potent functional epitope of SOST. (D-a) SOST 131–163 fragment (highlighted in yellow) is located within the loop3 domain of SOST protein. (D-b) Docking studies indicate that SOST 131–163 fragment interacts with ROMO light chain, yielding a binding free energy of -25.8 kcal/mol and an interface area of 712.9 Ų. (D-c) Additionally, SOST 131–163 fragment can bind to the ROMO heavy chain, resulting in a binding free energy of -33.19 kcal/mol and an interface area of 451.6 Ų. (E) CTL epitopes within SOST 131–163 sequence include two strong binder epitopes and four weak binder epitopes. (F) HTL epitopes in SOST 131–163 sequence comprise one strong binder epitope and four weak binder epitopes. Predictions of B cell epitopes for SOST 131–163 sequence are illustrated, including predicted linear B cell epitopes (G) and predicted discontinuous B cell epitopes (H) .

Article Snippet: In brief, 1 μg/mL of human SOST protein (MedChemExpress Inc.) was coated onto the wells of MaxiSorp microtiter plates (Thermo Fisher Scientific Inc.) and incubated overnight at 4°C.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Functional Assay, Sequencing

Journal: European Journal of Medical Research

Article Title: Pirenzepine exhibits anti-prostate cancer activity and enhances checkpoint inhibitor-based immunotherapy by targeting STING

doi: 10.1186/s40001-025-03520-4

Figure Lengend Snippet: A Schematic diagram of the subcutaneous tumor formation experiment in C57BL/6c mice; B – D C57BL/6c mice with RM1-tumor received PZP treatment (16 mg/kg, i.p. daily) and anti-PD1 treatment (CAT#BE0146, 200 µg per mouse, BioXCell) or an IgG isotype control (CAT#BE0089, BioXCell) intraperitoneally once every 2 days; C Tumor growth curve, data were presented as mean ± SD (n = 6), ** P ≤ 0.01, *** P ≤ 0.001; D Tumor mass, data were presented as mean ± SD (n = 6), **** P ≤ 0.0001; E – G C57BL/6c mice with RM1-shSting-tumor received PZP treatment (16 mg/kg, i.p. daily) and anti-PD1 treatment (CAT#BE0146, 200 µg per mouse every time, BioXCell) or an IgG isotype control (CAT#BE0089, BioXCell) intraperitoneally once every two days; F Tumor growth curve, data were presented as mean ± SD (n = 6), ns, not significant; G Tumor mass data were presented as mean ± SD (n = 6), ns not significant

Article Snippet: The PZP (CAT#HY-17037A, MedChemExpress) was dissolved in DMSO.

Techniques: Control